Organization | University of Oulu

University of Oulu Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Oulu Finland (1958)

Organization Overview

First Clinical Trial

1994

NCT00966264

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Children's Hospital, Univ. of Oulu | Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland | Dept Ob-Gyn, Univeristy of Oulu | Dept Ob-Gyn, University of Oulu | Dept of Otolaryngology, University of Oulu, Finland | Dept of Pediatrics and Adolescents, Oulu University Hospital, Box 23, 90029 OYS, Finland | Dept. of Pediatrics, Oulu University Hospital | Medical Informatics and Statistics Research Group, University of Oulu | Ooulu | Oulu Central Hospital, Dept. of Obstetrics & Gynecology | Oulun yliopisto | Oulu Univerisity Hospital | Oulu University | Oulu University and Oulu University Hospital | Oulu University Central Hospital, Department of Neurology | Oulu University Hospital | Oulu University Hospital, Department of Gynecology and Obstetrics | Oulu University Hospital, Department of Obstetrics and Gynecology | Oulu University Hospital - Dept of Internal Medicine | Oulu University Hospital, Dept of Pediatrics; PEDEGO Research unit and MRC Oulu, University of Oulu | Research Unit of Oral Health Sciences, University of Oulu, Finland | Tuula Toljamo | University hospital of Oulu | University Hospital of Oulu | University Hospital of Oulu, Finland | University Hospital of Oulu, Finland and Oregon Health Sciences University, Oregon USA | University of Oulu | University of Oulu, Department of dental health | University of Oulu, Department of Pediatrics | University of Oulu. Oulu University of Applied Sciences

Active Ingredients

Drugs in Phase 4 Trials (29)

acetaminophen (tylenol) (4 trials)

betamethasone (celestone) (1 trial)

clavulanate (Augmentin) (3 trials)

cyclosporine (sandimmune) (1 trial)

desogestrel (Mercilon) (2 trials)

diclofenac (voltaren) (1 trial)

dienogest (natazia) (1 trial)

enoxaparin (lovenox) (1 trial)

escherichia coli nissle 1917 (1 trial)

estradiol (progynon depot) (2 trials)

ethinyl estradiol (Estinyl) (3 trials)

fentanyl (Innovar) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

ibuprofen (motrin) (2 trials)

imatinib (gleevec) (1 trial)

infliximab (remicade) (1 trial)

ketamine (ketalar) (1 trial)

metformin (glucophage) (1 trial)

methylprednisolone (medrol) (1 trial)

mometasone (elocon) (1 trial)

nicotine (nicorette) (2 trials)

prednisolone (hydeltra) (1 trial)

prednisone (meticorten) (1 trial)

procaine benzylpenicillin (novocaine) (3 trials)

remdesivir (1 trial)

rifampin (4 trials)

sodium chloride (3 trials)

varenicline (chantix) (2 trials)

Drugs in Phase 3 Trials (6)

amiodarone (cordarone) (1 trial)

insulin human (humulin) (1 trial)

norgestrel (Ovral) (1 trial)

sitagliptin (januvia) (2 trials)

tafluprost (zioptan) (1 trial)

vernakalant hydrochloride (1 trial)

Drugs in Phase 2 Trials (4)

allopurinol (zyloprim) (1 trial)

liraglutide (victoza) (3 trials)

venetoclax (venclexta) (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 1 Trials (2)

clodronate disodium (1 trial)

egfrviii-specific hinge-optimized cd3 ζ-stimulatory/41bb-co-stimulatory chimeric antigen receptor autologous t-lymphocytes (1 trial)

Drugs in Other Trials (20)

acetylsalicylic acid (aspirin) (1 trial)

atorvastatin (lipitor) (1 trial)

azithromycin (zithromax) (1 trial)

benzocaine (1 trial)

birch pollen allergen extract (1 trial)

cefuroxime (zinacef) (1 trial)

cranberry (1 trial)

ertapenem (invanz) (3 trials)

glucose (1 trial)

levofloxacin (levaquin) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

metronidazole (flagyl) (1 trial)

moxifloxacin (avelox) (2 trials)

norelgestromin (Evra) (1 trial)

platelets (1 trial)

tacrolimus (prograf) (1 trial)

triamcinolone (kenalog) (1 trial)

whole wheat allergenic extract (1 trial)

xylitol (1 trial)

xylometazoline (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Spontaneous (Phase 3)

Atrial Fibrillation (Phase 3)

Back Pain (Phase 2)

Birth Weight (Phase 2)

Cerebral Hemorrhage (Phase 4)

Communicable Diseases (Phase 4)

Diabetes, Gestational (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Ductus Arteriosus, Patent (Phase 2)

Emergencies (Phase 4)

Fatty Liver (Phase 4)

Fever (Phase 4)

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Glomerulonephritis (Phase 4)

Hemorrhage (Phase 4)

Hypertension (Phase 3)

Hypokalemia (Phase 4)

IgA Vasculitis (Phase 4)

Infections (Phase 4)

Infertility (Phase 3)

Insulin Resistance (Phase 4)

Joint Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Liver Diseases (Phase 4)

Low Back Pain (Phase 2)

Menorrhagia (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 4)

Ocular Hypertension (Phase 3)

Osteoarthritis, Hip (Phase 1)

Otitis (Phase 4)

Otitis Media (Phase 4)

Otitis Media, Suppurative (Phase 3)

Pain, Postoperative (Phase 4)

Phimosis (Phase 4)

Polycystic Ovary Syndrome (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Pregnancy in Diabetics (Phase 4)

Premature Birth (Phase 4)

Purpura (Phase 4)

Recurrence (Phase 4)

Respiratory Distress Syndrome (Phase 4)

Respiratory Distress Syndrome, Newborn (Phase 4)

Respiratory Tract Infections (Phase 4)

Seizures (Phase 4)

Seizures, Febrile (Phase 4)

Sinusitis (Phase 4)

Syndrome (Phase 3)

Thromboembolism (Phase 4)

Toxemia (Phase 3)

Urinary Tract Infections (Phase 4)

Venous Thromboembolism (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 55
# of Trial APIs: 61